UPDATE: Abbott (ABT) Tops Q3 EPS by 1c, Updates FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Nasdaq notches record high close as investors focus on earnings
Abbott Labs (ABT) PT Raised to $65 at Jefferies
October 19, 2017 9:25 AM EDTJefferies raised its price target on Abbott Labs (NYSE: ABT) to $65.00 (from $58.00) while maintaining a Buy rating following the company's 3Q earnings report. Org growth in 3Q of +5.6% was the best in 2 years and largely validates the recent portfolio moves. Driving the performance... More
Abbott Labs (ABT) PT Raised to $60 at Morgan Stanley
October 19, 2017 8:54 AM EDTMorgan Stanley raised its price target on Abbott Labs (NYSE: ABT) to $60.00 (from $53.00) while maintaining a Equalweight rating.
... MoreAbbott Labs (ABT) PT Raised to $63 at Stifel Following 3Q Release
October 18, 2017 5:06 PM EDTStifel raised its price target on Abbott Labs (NYSE: ABT) to $63.00 (from $58.00) while maintaining a Buy rating following the company's 3Q earnings report. The company reported above-expectation 5.6% comparable operational sales growth and above-consensus EPS at $0.66 (vs. $0.65 Consensus). positive 3Q highlights included: key product approvals, improving pipeline... More



